– Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease – Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF time sustained for at least two years EMERYVILLE,...
HOUSTON, Feb. 11, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a...
Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a...
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 /PRNewswire/ — T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD),...
– After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination – – Findings To Be Presented During an Oral Session at the 2020...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce its plan to initiate a Phase I clinical trial for Berubicin in...
Email
Text